NEW YORK, July 30 – Exelixis of South San Francisco, Calif., has filed a shelf registration with the Securities and Exchange Commission to offer up to $150 million in common stock.

The company said it was considering raising additional funds to help support the development of cancer drug rebeccamycin, which it recently acquired from Bristol-Myers Squibb, as well as for other drug discovery and corporate activities.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.